[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536644":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":23,"locations":32,"responsibleParty":62,"collaborators":66,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Ludwig-Maximilians - University of Munich","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A",null,"HIV-exposed infants and their mothers enrolled in the study",[13],"Procedure: Maternal HIV viral load testing at delivery for VHT risk assessment",{"label":15,"type":10,"description":16,"interventionNames":10},"Cohort B","HIV-positive infants, identified in the first 12 weeks, and their mothers will be rolled over from Cohort A to Cohort B for long-term follow-up for up to 12 months.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Maternal HIV viral load testing at delivery for VHT risk assessment","Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.",[9],[24,30],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Arne Kroidl, MD","CONTACT","+49-89-4400","59816","Arne.Kroidl@med.uni-muenchen.de",{"name":31,"role":26,"phone":10,"phoneExt":10,"email":10},"Amy Heilman",[33,50],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Centro de Investigacao Operacional de Beira (CIOB), Instituto Nacional de Saúde (INS), Ministério da Saúde,","RECRUITING","Beira","Mozambique","MZ",{"type":40,"coordinates":41},"Point",[42,43],34.83889,-19.84361,{"lat":43,"lon":42},[46,48],{"name":47,"role":26,"phone":10,"phoneExt":10,"email":10},"Joaquim Lequechane",{"name":49,"role":26,"phone":10,"phoneExt":10,"email":10},"Ilesh Jani, MD, PhD",{"facility":51,"status":35,"city":52,"state":52,"zip":10,"country":53,"countryCode":10,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"National Institute for Medical Research (NIMR)","Mbeya","Tanzania",{"type":40,"coordinates":55},[56,57],33.45,-8.9,{"lat":57,"lon":56},[60],{"name":61,"role":26,"phone":10,"phoneExt":10,"email":10},"Issa Sabi, MD, PhD",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Michael Hoelscher","Director, Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich,",[67,70,72],{"name":68,"class":69},"National Institute for Medical Research (NIMR) - Mbeya Medical Research Centre (MMRC)","UNKNOWN",{"name":71,"class":69},"Instituto Nacional de Saúde (INS), Ministério da Saúde",{"name":73,"class":6},"University of Liverpool","100536644","increasing-neonatal-hiv-test-and-treat-to-maximize-the-long-term-impact-on-infant-health-and-novel-infant-antiretroviral-treatment-100536644",false,"NCT06267508","Increasing Neonatal HIV Test and Treat to Maximize the Long-Term Impact on Infant Health and Novel Infant Antiretroviral Treatment","LIFE2Scale","Inclusion Criteria:\n\n1. Voluntary and informed consent of the mother for her own study participation (if applicable);\n2. Voluntary and informed consent of the legal guardian of the child for participation of the child in the study;\n3. Mothers\u002Flegal guardians ≥18 years of age;\n4. Documented maternal HIV infection;\n5. Willingness to consent to HIV testing for the child and herself (or just her child); and\n6. Willingness to consent to active tracing including home tracing.\n\n   Exclusion Criteria:\n7. Deficiency in the mother, rendering it difficult, if not impossible, for her or her infant to take part in the study or understand the information provided to her.\n8. Having delivered more than 72h (3 days) ago;\n9. Prisoners;\n10. Women presenting with an emergency requiring immediate medical assistance if not resolved at study inclusion;\n11. Stillbirths;\n12. Infant requiring emergency care (e.g. immediate or rapid occurring life threatening conditions, resuscitation, prolonged obstetric related intensive care, severe jaundice) or born with severe malformation;\n13. If within the discretion of the investigator based on recommendation of the gynaecologist or paediatrician in charge study participation would possibly add not acceptable risk or burden to the mother or infant (e.g. significant congenital malformation, health deficiencies, very low birth weight less than 1500g); or\n14. Unlikely to comply with protocol as judged by the principal investigator or his designate","FEMALE","18 Years",{"count":84,"type":85},6000,"ESTIMATED","OBSERVATIONAL","This study aims to improve HIV healthcare services for mothers living with HIV and their newborns in Tanzania and Mozambique. The main questions it aims to answer are: 1) does enhancing screening with maternal HIV viral load monitoring at delivery identify more mother-child pairs at high-risk for HIV vertical transmission? and 2) are high-risk infants linked to appropriate prevention and care? The study will expand access to HIV testing services to more rural settings using a hub-and-spoke referral system.",[89,90,91,92,93],"Vertical Human Immunodeficiency Virus Transmission","HIV Infection Pediatric","Infant Death","Infant Morbidity","Infant, Newborn, Diseases",[95,96,97,98],"Prevention of Vertical HIV Transmission (PVHT)","Infant HIV Prophylaxis","Early Infant HIV Diagnosis","Infant Antiretroviral Treatment","2024-11-14",{"date":101,"type":102},"2024-11-18","ACTUAL",{"date":104,"type":102},"2024-04-30",{"date":106,"type":85},"2025-12",{"name":64,"class":6},2]